March 5 (Reuters) – Shares of Swiss skincare company Galderma opened higher on Thursday after it reported 17.7% growth in full-year net sales and gave an upbeat guidance for 2026.
The annual net sales were $5.21 billion, with the strongest growth coming from its Therapeutic Dermatology business, where sales grew more than 50% largely thanks to the recently launched Nemluvio product, which is used to treat chronic skin conditions atopic dermatitis and prurigo nodularis.
The company expects net sales growth of 17% to 20% and a core profit margin of about 26% on a constant-currency basis for 2026.
The shares gained around 7% by 0850 GMT, with Vontobel analysts saying the guidance was stronger than expected.
(Reporting by Marleen Kaesebier in Gdansk, editing by Milla Nissi-Prussak)
